Blink Health: A new approach to generic drug savings
Jeffrey Clark - Posted: 2/17/2016
Blink Health: A new approach to generic drug savings
Mallinckrodt joins Valeant, others in drug pricing debate
Jeffrey Clark - Posted: 1/5/2016
Mallinckrodt president & CEO Mark Trudeau discusses the companys success with Achtar and the decision to raise prices. Acthar was developed in the 1950s by a division of Armour & Company, the meatpacking company that once ruled the Union Stock Yards [...]
Cool Technology: MIT breaks new boundaries with smart bandage
Jeffrey Clark - Posted: 12/15/2015
A team at the Massachusetts Institute of Technology has come up with a strong, stretchy, wet bandage and have embedded it with tiny electronics, LED lights and microchannels to deliver drugs. NBC News
Martin Shkreli continues to play the game, draws ire of Big Pharma
Jeffrey Clark - Posted: 12/4/2015
Embattled Turing Pharmaceuticals CEO Martin Shkreli took the stage yesterday at the Forbes Healthcare Summit in New York City. In a very public setting, moderators gave him the chance to backpedal from his aggressive pricing stance from earlier this [...]
Saunders rumored as chosen CEO for Allergan/Pfizer combination
Jeffrey Clark - Posted: 11/11/2015
Allergan and Pfizer have entered into what are described as ‘amiable discussions’ regarding a potential merger of two Big Pharma giants.  The deal would be structured as an inversion and complete the task that Pfizer CEO Ian Read set out for when he [...]
FDA targets another personal DNA testing company
Jeffrey Clark - Posted: 11/10/2015
The FDA has their sights set on another personal genetic testing company.  This week, the agency sent a letter to privately held DNA4Life over the companys sale of an unapproved direct-to-consumer gene test to predict drug response.  T[...]
Kid-sized medical devices are a struggle for young patients
Jeffrey Clark - Posted: 11/9/2015
A fascinating article about the struggle to bring childrens medical devices to market, in comparison to those full-sized devices for a much larger adult patient population. Huffington Post
Pfizer/Allergan could be the pinnacle of deals
Jeffrey Clark - Posted: 10/29/2015
In an life sciences business environment filled with over-the-top mergers and acquisitions, we may just be approaching the granddaddy of them all. Today, Allergan confirmed that it has been approached by Pfizer and is in talks regarding a potential d[...]
Stephen Ubl moves on from Advamed, joins PhRMA
Jeffrey Clark - Posted: 10/28/2015
[soundcloud url="" params="color=ff5500" width="100%" height="166" iframe="true" /] With the Advamed conference in San Diego now completed, President & CEO Stephen Ubl is moving on to lead the Pharmaceutical[...]
San Diego company undercuts Turing on $$$$ generic drug
Jeffrey Clark - Posted: 10/23/2015
In a huge PR victory and checkmate to a villainized life sciences CEO, San Diego-based Imprimis Pharmaceuticals will begin selling Daraprim, whose price was famously jacked up to $750 per pill for just $0.99 per pill.  Imprimis is a compounding drug [...]
Valeant under fire, stock losing value
Jeffrey Clark - Posted: 10/22/2015
Valeant Pharmaceuticals has lost more than 1/3 of its value in the past month. Most of the losses stem from government inquiries into Valeant practices regarding drug pricing and accounting fraud. Just this week, Valeant was subpoenaed by federal pro[...]
Daiichi Sankyo shifts focus due to mounting pressures, announces more layoffs
Jeffrey Clark - Posted: 10/20/2015
Japanese pharmaceutical company Daiichi Sankyo is fundamentally shifting its focus from its primary-care product portfolio to a specialty focus. The company will moving forward compete in cardiovascular, pain and cancer drugs. With limited new R&D dr[...]
Drug industry in the crosshairs as enemy of Democratic presidential candidates
Jeffrey Clark - Posted: 10/14/2015
No one yet knows how the 2016 US Presidential election will shake out. But is it any wonder why most in the life sciences industry are on the side of the Republicans? For the final questions during last nights Democratic debate, each of the five cand[...]
Advamed 2015 in San Diego
Jeffrey Clark - Posted: 10/6/2015
Other than JPMorgan in January, Advamed is still the one event that life sciences CEOs feel compelled to attend each year.  This fall, the event is being held in San Diego, championed by outgoing Advamed President Stephen Ubl and this years Chairman [...]
So, what is Theranos? A primer.
Jeffrey Clark - Posted: 10/5/2015
Valeant under Congressional fire for price increases
Jeffrey Clark - Posted: 10/1/2015
In the midst of their 2014 acquisition battle, Allergan and many others across the industry took some heavy-handed swipes at Valeant Pharmaceuticals deriding their business model as unsustainable. Less than a year later, that forecast may be coming i[...]
Theranos CEO quietly upends an industry, may change the world
Jeffrey Clark - Posted: 9/30/2015
We are trying to solve a different problem than the lab industry is trying to solve. Theranos founder & CEO Elizabeth Holmes shares her story of upending the medical testing industry by developing a system to detect disease early on and with less blo[...]
Alnylam CEO talks new cholesterol frontiers
Jeffrey Clark - Posted: 9/29/2015
Alnylam Pharma CEO John Maraganore discusses preliminary but promising results on a new cholesterol-lowering drug that shows remarkable durability and reduces dosing.
ConforMIS sets sights on redefining orthopedic implants
Jeffrey Clark - Posted: 9/28/2015
ConforMIS founder and CEO Dr. Philipp Lang discusses the companys personalized joint replacement for patients, which is attempting to disrupt the orthopedic implants market with custom-fitted implantable devices for individual patients.
Cool Technology: Airing reinvents sleep apnea treatment
Jeffrey Clark - Posted: 9/25/2015
Airing has invented a micro CPAP device that has no hoses, no cords, and no masks. They have also led the most successful crowdfunding campaign for a life sciences products in history, having raised over $1M. Airing
Clinton takes aim at drug pricing and life sciences innovation
Jeffrey Clark - Posted: 9/24/2015
On Tuesday, Hillary Clinton announced her proposal for lowering the cost of prescription drugs at a public forum in Des Moines, Iowa. The move followed her rebuke of Turing Pharmaceuticals and their CEO Martin Shkreli who increased the price of a new[...]
Turing CEO tagged as a villain, changes course after media firestorm
Jeffrey Clark - Posted: 9/23/2015
Turing Pharmaceuticals acquired a drug from Impax Laboratories in August for $55 million and subsequently raised the price from $13.50 to $750 per pill. The company stated that profits from the increase would be used to develop better treatment for t[...]
Hillary Clinton pummels drug stocks with a single tweet
Jeffrey Clark - Posted: 9/22/2015
Drug stocks have been on fire for years. The iShares biotech ETF has skyrocketed nearly 300% over the past five years, vastly outperforming the broader markets. But yesterday, one tweet by a prominent Presidential candidate delivered a blow. Pharmace[...]
Gilead raises $10B in debt. Next move?
Jeffrey Clark - Posted: 9/18/2015
Four years ago, when Gilead bought Pharmasset (a company of less than 100 employees) for $11 billion in cash, there was a considerable amount of criticism.  That deal brought into Gileads portfolio the biggest drug of all time.  Sovaldi has become a [...]
Medtronic acquires naming rights to NFL stadium plaza
Jeffrey Clark - Posted: 9/16/2015
Medtronic will extend its brand to the new Minnesota Vikings stadium. The company has agreed to pay an undisclosed sum to purchase the naming rights to the plaza at the entrance of the new US Bank Stadium in Minneapolis.   The deal, which will expand[...]
Blink Health: A new appro[...]
Blink Health: A new approach to generic drug savings
Mallinckrodt joins Valean[...]
Mallinckrodt president & CEO Mark Trudeau discusses the company’s success with Achtar and the decisi[...]
Cool Technology: MIT brea[...]
A team at the Massachusetts Institute of Technology has come up with a strong, stretchy, wet bandage[...]
Pfizer/Allergan could be [...]
In an life sciences business environment filled with over-the-top mergers and acquisitions, we may j[...]
Valeant under fire, stock[...]
Valeant Pharmaceuticals has lost more than 1/3 of its value in the past month. Most of the losses st[...]